Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 264Glioma 109Brain Neoplasms 104Gliosarcoma 85Central Nervous System Neoplasms 64Astrocytoma 61Melanoma 46Oligodendroglioma 44Neuroblastoma 28Recurrence 22Neoplasm Metastasis 18Neoplasms 16Medulloblastoma 16Ependymoma 16Sarcoma, Ewing 13Lymphoma 13Sarcoma 12Rhabdomyosarcoma 11Neuroendocrine Tumors 11Lung Neoplasms 11Diffuse Intrinsic Pontine Glioma 10Small Cell Lung Carcinoma 9Neuroectodermal Tumors, Primitive 7Colorectal Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Osteosarcoma 6Pinealoma 5Optic Nerve Glioma 5Choroid Plexus Neoplasms 5Carcinoma, Non-Small-Cell Lung 5

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Efficacy and Safety × Temozolomide × Clear all
NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡